Blinatumomab + Blinatumomab + HyperCVAD

Phase 3Recruiting

0 views this week 0 watching⚡ Active

Interest: 47/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

✓

Phase 2

Phase 3

Approved

Indication / Disease

Philadelphia Chromosome Negative B-cell Precursor Acute Lymphoblastic Leukemia

Conditions

Philadelphia Chromosome Negative B-cell Precursor Acute Lymphoblastic Leukemia

Trial Timeline

Jun 11, 2026 → Aug 9, 2033

NCT ID

NCT07223190

About Blinatumomab + Blinatumomab + HyperCVAD

Blinatumomab + Blinatumomab + HyperCVAD is a phase 3 stage product being developed by Amgen for Philadelphia Chromosome Negative B-cell Precursor Acute Lymphoblastic Leukemia. The current trial status is recruiting. This product is registered under clinical trial identifier NCT07223190. Target conditions include Philadelphia Chromosome Negative B-cell Precursor Acute Lymphoblastic Leukemia.

What happened to similar drugs?

2 of 7 similar drugs in Philadelphia Chromosome Negative B-cell Precursor Acute Lymphoblastic Leukemia were approved

Approved (2) Terminated (1) Active (4)

❌NilotinibNovartisPhase 3

🔄NilotinibNovartisPhase 3

🔄Asciminib + NilotinibNovartisPhase 3

✅NilotinibNovartisApproved

🔄Imatinib + Nilotinib + Bosutinib + Dasatinib + AsciminibNovartisPhase 3

✅AsciminibNovartisApproved

🔄Blinatumomab + Low-intensity chemotherapy regimen + SOC chemotherapy regimenAmgenPhase 3

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (1)

NCT ID	Phase	Status	Start	Completion	Indication
NCT07223190	Phase 3	Recruiting	Jun 11, 2026	Aug 9, 2033	Philadelphia Chromosome Negative B-cell Precursor Acute Lymphoblastic Leukemia

Competing Products

20 competing products in Philadelphia Chromosome Negative B-cell Precursor Acute Lymphoblastic Leukemia

See all competitors

Product	Company	Stage	Hype Score
Imatinib Mesylate	Novartis	Phase 2	35
Nilotinib	Novartis	Phase 3	32
Nilotinib	Novartis	Phase 3	40
STI571 400 mg + STI571 600 mg	Novartis	Phase 2	35
Induction Phase + Re-Induction Phase + Post-Remission + Maintenance	Novartis	Phase 2	42
nilotinib	Novartis	Phase 2	35
Asciminib + Nilotinib	Novartis	Phase 3	44
imatinib mesylate	Novartis	Phase 2	35
Blinatumomab + Asciminib	Novartis	Phase 1/2	39
Asciminib	Novartis	Phase 1	36
Asciminib Pediatric formulation group + Asciminib Adult formulation group	Novartis	Phase 1/2	39
Nilotinib + LDE225	Novartis	Phase 1	29
Nilotinib	Novartis	Approved	43
Imatinib + Nilotinib + Bosutinib + Dasatinib + Asciminib	Novartis	Phase 3	44
Asciminib	Novartis	Approved	47
Blinatumomab	Amgen	Phase 2	35
Treatment with blinatumomab given subcutaneously.	Amgen	Phase 2	42
Blinatumomab + Low-intensity chemotherapy regimen + SOC chemotherapy regimen	Amgen	Phase 3	47
Bosutinib	Pfizer	Phase 1/2	36
Bosutinib + Bosutinib	Pfizer	Phase 1	29